RT Journal Article
SR Electronic
T1 Risk interactions of coronavirus infection across age groups after the peak of COVID-19 epidemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.17.20105049
DO 10.1101/2020.05.17.20105049
A1 Yu, Xinhua
YR 2020
UL http://medrxiv.org/content/early/2020/07/06/2020.05.17.20105049.abstract
AB Background the COVID-19 pandemic has incurred significant disease burden worldwide, particularly on elderly population. This study aims to explore how risks of infection interact across age groups using data from South Korea.Methods Daily new COVID-19 cases from March 10 to April 30, 2020 were scraped from online open sources. A multivariate vector autoregressive model for time series count data was used to examine the risk interactions across age groups. Case counts from previous days were included as predictors to dynamically examine the change of risk patterns.Results In South Korea, the risk of coronavirus infection among elderly people was significantly affected by other age groups. An increase of virus infection among people aged 20-39 was associated with a double risk of infection among elderly people. Meanwhile, an increase in virus infection among elderly people was also significantly associated with risks of infection among other age groups. The risks of infection among younger people were relatively unaffected by that of other age groups.Conclusions Protecting elderly people from coronavirus infection could not only reduce the risk of infection among themselves but also ameliorate the risks of virus infection among other age groups. Such interventions should be effective and for long term.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFedEx Institute of Technology, University of Memphis Data cluster seed awardAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval is needed. The data are publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGitHub address laterSARS-CoV-2severe acute respiratory syndrome coronavirus 2COVID-19coronavirus infectious disease 2019GAMgeneralized additive modelVARvector autoregressive regressionNBnegative binomial modelREMLrestricted maximum likelihoodPMFprobability mass function